Company Overview

Changing the Patient Treatment Paradigm with Precision Medicine for Autoimmune Diseases

With new scientific insights and advanced technologies, Rheos Medicines is dedicated to dramatically improving outcomes for patients by leading a new era of treating autoimmune and inflammatory diseases with precision medicines. We are pioneers in targeting and identifying the molecular characteristics and patient subsets for these complex diseases.

Rheos is built on groundbreaking science in immunometabolism, which enables us to understand the dysregulated mechanisms that can drive autoimmune and inflammatory diseases. We have assembled an experienced and passionate team of scientists, drug developers, and industry-leading advisors to advance a novel pipeline of molecular targeted therapies, along with molecular signatures that predict patient response. We work as an inspired team, collaborating and building on our unique talents.

MasterCell_wDiagram

Moving Beyond Today’s Approaches: Even with the significant progress over the years to evolve treatments from delivering broad immunosuppression for autoimmune and inflammatory diseases, therapeutic effectiveness is not achieved in all patients, highlighting the heterogeneity of underlying disease mechanisms. Rheos’s insights into the metabolic hubs that fuel the many immune cell subtypes within the immune system is making it possible to discover and develop new, more effective therapies.

A New Metabolic Lens: With our MetPM platform, Rheos uncovers insights into the central, networked hubs of immune cell metabolism that regulate the function of immune cell subtypes. This opens new possibilities to discover and develop novel therapies that target key mechanisms of immune-mediated diseases.

Molecular Targeted Medicines, Patient Subsets: With Rheos’s molecularly-targeted approach, our small molecule medicines are designed to deliver better efficacy with fewer side effects. Additionally, our platform identifies molecular signatures to stratify patients and move the field toward a precision medicine approach for autoimmune and inflammatory diseases.

Our vision at Rheos is to make precision medicine a reality for patients burdened by autoimmune and inflammatory diseases. We believe the time is right to create a new generation of treatments in this field using a precision medicine approach, as we have seen it utilized successfully in other disease areas, such as cancer. Rheos is changing the status quo and developing precision medicines designed for specific subsets of patients in autoimmune and inflammatory diseases, enabling us to select the right therapy for every patient.